Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-term, Prospective,Multinational, Parallel-cohort Study Monitoring Safety in Patients With MS Newly Started With Fingolimod Once Daily or Treated With Another Approved Disease-modifying Therapy

NCT01442194 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT01442194
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01442194 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-term, Prospective,Multinational, Parallel-cohort Study Monitoring Safety in Patients With MS Newly Started With Fingolimod Once Daily or Treated With Another Approved Disease-modifying Therapy
Lead sponsor
Novartis Pharmaceuticals
Phase
Observational
Overall status
Completed
Start date
August 1, 2011
Completion date
July 10, 2020
Enrollment
3,076 (actual)
Sites
238

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis